AbbVie Partners with BigHat Biosciences to Develop Next-Generation Therapeutic Antibodies Using AI and Machine Learning

Dec 07, 2023 09:39 CST Updated 09:39

AbbVie

Innovative Drug Developer

BigHat Biosciences

Antibody Design Platform Developer

Recently, AbbVie announced a research collaboration with BigHat Biosciences to discover and develop next-generation therapeutic antibodies in the fields of oncology and neuroscience. Working closely with AbbVie, BigHat will utilize its Milliner™ platform, a set of machine learning technologies integrated with high-speed wet labs, to guide the design and selection of high-quality antibodies for multiple therapeutic targets. Previously, the company had already established R&D collaborations with Merck and Amgen.

Under the terms of the agreement, BigHat will receive a $30 million upfront payment and may be eligible for up to approximately $325 million in total R&D milestones, with the potential for additional commercial milestones and tiered royalties on net sales.

Jonathon Sedgwick, Ph.D., Vice President of AbbVie and Global Head of Discovery Research, stated:"This collaboration further demonstrates our commitment to integrating AI/ML-based approaches into drug discovery and development, as we work to accelerate advancements in oncology and neuroscience to deliver better medicines more quickly. We look forward to collaborating with the team at BigHat Biosciences, Inc. to design novel antibody-based therapies that may help address the ongoing unmet needs faced by patients."

BigHat Biosciences, Inc. CEO Mark DePristo said:"We are thrilled to partner with AbbVie, a global leader in driving innovation in drug development, and look forward to leveraging our Milliner™ platform to help design the next generation of therapeutic antibodies, enabling rapid optimization of multiple critical parameters including functionality and developability, to help deliver complex antibodies with improved properties more quickly."

Follow the official account below to explore the world with you!